[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368682-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-368682-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","harnessing-organoid-technology-in-urological-cancer-advances-and-applications-in-urinary-system-tumors","Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors","","The organoid approach preserves the intricate molecular and genetic characteristics of tumor tissues, enabling precision oncology research focused on therapy discovery and in vitro validation of drug efficacy. Organoids support studies of urological cancers by facilitating work on tumorigenesis, drug testing, and the design of therapeutic combinations. Compared with traditional 2D cell cultures and patient-derived xenograft (PDX) models, organoids better mirror the in vivo environment. Modern platforms combine 3D bioprinting, co-culture, microfluidics, and AI to improve precision, scalability, and efficiency. The review outlines organoid establishment and translational potential across prostate, bladder, and renal cancers, including growing synergy with bioengineering innovations.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/harnessing-organoid-technology-in-urological-cancer-advances-and-applications-in-urinary-system-tumors/368682/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/harnessing-organoid-technology-in-urological-cancer-advances-and-applications-in-urinary-system-tumors/368682.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"Which urinary system cancers are covered in the review?","Question",{"text":63,"@type":64},"The review addresses the three major urogenital system cancers: prostate, bladder, and renal cancers, describing organoid technologies from basic research toward clinical applications.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},368682,1790199681,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":101,"preview_page_count":33,"preview_urls":137},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Wang et al.  \nWorld Journal of Surgical Oncology (2025) 23:295 [https://doi.org/10.1186/s12957-025-03948-2](https://doi.org/10.1186/s12957-025-03948-2)  \nWorld Journal of Surgical Oncology  \n REVIEW Open Access  \nHarnessing organoid technology  \nin urological cancer: advances and applications in urinary system tumors  \nXiaoting Wang1,2*, Danyan Lin2 and Ninghan Feng1,2*  \nAbstract  \nThe organoid approach preserves the intricate molecular and genetic characteristics of tumor tissues, playing a pivotal role in advancing precision oncology. This preservation enables the exploration of cancer therapies and in vitro validation of drug efficacy. Organoids have emerged as indispensable tools in the study of urological cancers, facilitating research on tumorigenesis, drug testing, and the development of therapeutic combinations. Their superiority over traditional 2D cell cultures and patient-derived xenograft (PDX) models lies in their enhanced ability to more accurately replicate the in vivo environment. Modern organoid platforms integrate 3D bioprinting, co-culture systems, microfluidics, and artificial intelligence to significantly improve the precision, scalability, and efficiency of cancer research. These integrated systems serve as powerful analytical tools, propelling the development of personalized therapies for urological malignancies. This article provides a comprehensive review of the establishment and potential of organoid technologies in treating the three major urogenital system cancers—prostate, bladder, and renal—highlighting their trajectory from basic research to clinical applications and their expanding synergy with bioengineering innovations.  \nKeywords Organoids, Urinary system tumors, Drug screening, Precision medicine, 3D culture  \n*Correspondence: Xiaoting Wang [xiaotingwang@msn.com](xiaotingwang@msn.com)[ ](xiaotingwang@msn.com)Ninghan Feng [n.feng@njmu.edu.cn](n.feng@njmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nWang et al. World Journal of Surgical Oncology (2025) 23:295 Page 2 of 16  \nGraphical Abstract  \nOrganoids serve as a bridge between preclinical models and personalized therapies, providing a key preclinical model for addressing urological tumors.  \nIntroduction  \nUrinary cancers, including prostate, bladder, and renal cancers, are major global health concerns. Prostate cancer ranks as the second most common malignancy in men and is the fifth leading cause of cancer-related death worldwide [1]. Bladder cancer, with 82,290 new cases and 16,710 deaths reported globally in 2023, is the tenth most prevalent cancer, exerting a significant strain on healthcare systems [2]. Kidney cancer accounting for 5% of all cancer cases, is also among the top ten most frequent malignancies [3]. In total, recent reports estimate 168,560 new cases ","cbCaihfF2u0d9VNS","https://ap.wps.com/l/cbCaihfF2u0d9VNS","pdf",2335873,16,"English","# Abstract\n# Introduction\n## Background on urological cancers\n## Limitations of traditional tumor research models\n## Organoid technology as an alternative","[{\"question\":\"Which urinary system cancers are covered in the review?\",\"answer\":\"The review addresses the three major urogenital system cancers: prostate, bladder, and renal cancers, describing organoid technologies from basic research toward clinical applications.\"}]","Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors | PDF",1790178040,[138,142,146,150],{"page_no":22,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5de5e6b4c5f273f9edb26470bc43af9.webp",983,1305,{"page_no":26,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cde847ca60961c4eef38565d04ca32e7.webp",982,1304,{"page_no":30,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6e21ec49a9a7f78a6b561397c73d852.webp",981,1303,{"page_no":33,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2344897f1fc51aa3eec81834d361d986.webp",980,1301]